Cord Blood America Updates Advantages of Las Vegas Laboratory in Analyst Interview; Explains Recent S1 Filing

Rochester, New York 11/06/2009 11:25 PM GMT (TransWorldNews)

Cord Blood America, Inc. (OTCBB: CBAI) addressed shareholder questions about their new laboratory in Las Vegas, and their recently refiled S1 with the SEC. The company's founder and CEO, Matthew Schissler, addressed these issues in an interview by Francis Gaskins.

Penny Stock Professor, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Penny Stock Picks.

Mr. Schissler discussed:

The S1 registration statement withdraws an earlier filing, saves the company money, and will not be used until necessary.

The Las Vegas lab reducing costs because lab services will no longer need to be outsourced.

The new lab's ability to increase revenue streams, with new opportunities to store other biological products.

The lab will also give Cord Blood America the opportunity to work alongside other stem cell companies in R&D.

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders.

Sign up for the free Penny Stock Professor newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.

About Us

Penny Stock Professor is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.

Please click here to read the full disclaimer.